{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T00:18:19Z","timestamp":1724372299160},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,21]]},"DOI":"10.7759\/cureus.67443","type":"journal-article","created":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T04:43:01Z","timestamp":1724301781000},"source":"Crossref","is-referenced-by-count":0,"title":["Unprecedented Megakaryocytic Blast Phase Transformation in Chronic Myeloid Leukemia After 16 Years of Tyrosine Kinase Inhibitor Therapy"],"prefix":"10.7759","author":[{"given":"Kaworu","family":"Takatsuna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuhei","family":"Kurosawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitomi","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aki","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Aisa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Nakazato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0007","article-title":"Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Shah NP","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, et al.. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2024, 22:43-69. 10.6004\/jnccn.2024.0007","journal-title":"J Natl Compr Canc Netw"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbmt.2019.06.028","article-title":"Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party","volume":"25","author":"Radujkovic A","year":"2019","unstructured":"Radujkovic A, Dietrich S, Blok HJ, et al.. Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT chronic malignancies working party. Biol Blood Marrow Transplant. 2019, 25:2008-2016.","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3000","article-title":"The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation","volume":"40","author":"Shimazu Y","year":"2022","unstructured":"Shimazu Y, Murata M, Kondo T, et al.. The new generation tyrosine kinase inhibitor improves the survival of chronic myeloid leukemia patients after allogeneic stem cell transplantation. Hematol Oncol. 2022, 40:442-56. 10.1002\/hon.3000","journal-title":"Hematol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/BF02982695","article-title":"Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis","volume":"76","author":"Hirose Y","year":"2002","unstructured":"Hirose Y, Kiyoi H, Iwai M, Yokozawa T, Ito M, Naoe T. Successful treatment with imatinib mesylate of a CML patient in megakaryoblastic crisis with severe fibrosis. Int J Hematol. 2002, 76:349-53. 10.1007\/BF02982695","journal-title":"Int J Hematol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.01638.x","article-title":"Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia","volume":"69","author":"Pelloso LA","year":"2002","unstructured":"Pelloso LA, Baiocchi OC, Chauffaille ML, Yamamoto M, Hungria VT, Bordin JO. Megakaryocytic blast crisis as a first presentation of chronic myeloid leukemia. Eur J Haematol. 2002, 69:58-61. 10.1034\/j.1600-0609.2002.01638.x","journal-title":"Eur J Haematol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20777","article-title":"Paraplegia as the presenting manifestation of extramedullary megakaryoblastic transformation of previously undiagnosed chronic myelogenous leukemia","volume":"82","author":"Bryant BJ","year":"2007","unstructured":"Bryant BJ, Alperin JB, Elghetany MT. Paraplegia as the presenting manifestation of extramedullary megakaryoblastic transformation of previously undiagnosed chronic myelogenous leukemia. Am J Hematol. 2007, 82:150-4. 10.1002\/ajh.20777","journal-title":"Am J Hematol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20797","article-title":"Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia","volume":"82","author":"Campiotti L","year":"2007","unstructured":"Campiotti L, Grandi AM, Biotti MG, Ultori C, Solbiati F, Codari R, Venco A. Megakaryocytic blast crisis as first presentation of chronic myeloid leukemia. Am J Hematol. 2007, 82:231-3. 10.1002\/ajh.20797","journal-title":"Am J Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.02.025","article-title":"Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia","volume":"32","author":"Pullarkat ST","year":"2008","unstructured":"Pullarkat ST, Vardiman JW, Slovak ML, Rao DS, Rao NP, Bedell V, Said JW. Megakaryocytic blast crisis as a presenting manifestation of chronic myeloid leukemia. Leuk Res. 2008, 32:1770-5. 10.1016\/j.leukres.2008.02.025","journal-title":"Leuk Res"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3332\/ecancer.2013.375","article-title":"A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7)","volume":"7","author":"Karkuzhali P","year":"2013","unstructured":"Karkuzhali P, Shanthi V, Usha T. A case of chronic myeloid leukaemia presenting as megakaryocytic blast crisis (AML M7). Ecancermedicalscience. 2013, 7:375. 10.3332\/ecancer.2013.375","journal-title":"Ecancermedicalscience"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.57.608","article-title":"[Chronic myeloid leukemia relapsing ten years after allogenic bone marrow transplantation]","volume":"57","author":"Hino Y","year":"2016","unstructured":"Hino Y, Doki N, Yamamoto K, et al.. [Chronic myeloid leukemia relapsing ten years after allogenic bone marrow transplantation]. Rinsho Ketsueki. 2016, 57:608-12. 10.11406\/rinketsu.57.608","journal-title":"Rinsho Ketsueki"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12253-018-0484-7","article-title":"CML with megakaryocytic blast crisis: report of 3 cases","volume":"25","author":"Khemka R","year":"2019","unstructured":"Khemka R, Gupta M, Jena NK. CML with megakaryocytic blast crisis: report of 3 cases. Pathol Oncol Res. 2019, 25:1253-8. 10.1007\/s12253-018-0484-7","journal-title":"Pathol Oncol Res"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02628-8","article-title":"Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation","volume":"110","author":"Sasaki H","year":"2019","unstructured":"Sasaki H, Mitani S, Kusumoto S, et al.. Pre- and post-transplant ponatinib for a patient with acute megakaryoblastic blast phase chronic myeloid leukemia with T315I mutation who underwent allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2019, 110:119-23. 10.1007\/s12185-019-02628-8","journal-title":"Int J Hematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-019-02809-5","article-title":"Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation","volume":"111","author":"Ureshino H","year":"2020","unstructured":"Ureshino H, Shindo T, Sano H, et al.. Reconstitution of NK cells expressing KIR3DL1 is associated with reduced NK cell activity and relapse of CML after allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2020, 111:733-8. 10.1007\/s12185-019-02809-5","journal-title":"Int J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.htct.2020.07.004","article-title":"Megakaryocytic blast crisis in chronic myeloid leukiemia: an uncommon presentation in a common neoplasm","volume":"44","author":"Agrawal S","year":"2022","unstructured":"Agrawal S, Kumar K, Singh M, Chandra H. Megakaryocytic blast crisis in chronic myeloid leukiemia: an uncommon presentation in a common neoplasm. Hematol Transfus Cell Ther. 2022, 44:264-8. 10.1016\/j.htct.2020.07.004","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2023000447","article-title":"Resistance mutations in CML and how we approach them","volume":"2023","author":"Soverini S","year":"2023","unstructured":"Soverini S. Resistance mutations in CML and how we approach them. Hematology Am Soc Hematol Educ Program. 2023, 2023:469-75. 10.1182\/hematology.2023000447","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2009.03.013","article-title":"Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia","volume":"15","author":"Copelan EA","year":"2009","unstructured":"Copelan EA, Crilley PA, Szer J, et al.. Late mortality and relapse following BuCy2 and HLA-identical sibling marrow transplantation for chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2009, 15:851-5. 10.1016\/j.bbmt.2009.03.013","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.7757","article-title":"Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase","volume":"28","author":"Goldman JM","year":"2010","unstructured":"Goldman JM, Majhail NS, Klein JP, et al.. Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. J Clin Oncol. 2010, 28:1888-95. 10.1200\/JCO.2009.26.7757","journal-title":"J Clin Oncol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-019836","article-title":"Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia","volume":"109","author":"Carpenter PA","year":"2007","unstructured":"Carpenter PA, Snyder DS, Flowers ME, et al.. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007, 109:2791-3. 10.1182\/blood-2006-04-019836","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-04-082990","article-title":"Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia","volume":"110","author":"Olavarria E","year":"2007","unstructured":"Olavarria E, Siddique S, Griffiths MJ, et al.. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood. 2007, 110:4614-7. 10.1182\/blood-2007-04-082990","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771121","article-title":"Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia","volume":"130","author":"Carpenter PA","year":"2017","unstructured":"Carpenter PA, Johnston L, Fernandez HF, et al.. Posttransplant feasibility study of nilotinib prophylaxis for high-risk Philadelphia chromosome positive leukemia. Blood. 2017, 130:1170-2. 10.1182\/blood-2017-03-771121","journal-title":"Blood"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/280774-unprecedented-megakaryocytic-blast-phase-transformation-in-chronic-myeloid-leukemia-after-16-years-of-tyrosine-kinase-inhibitor-therapy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,22]],"date-time":"2024-08-22T04:43:05Z","timestamp":1724301785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/280774-unprecedented-megakaryocytic-blast-phase-transformation-in-chronic-myeloid-leukemia-after-16-years-of-tyrosine-kinase-inhibitor-therapy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,21]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.67443","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,21]]}}}